About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues$611 million in SYFOVRE® U.S. net product revenues, including $167 ...

Furthermore, intraocular injections are quite safe and result ... None of the patients developed drug-related adverse events. [88] In a Phase IIb, prospective, superiority trial, 449 patients ...

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

If you are worried about using this medicine, speak to your doctor or pharmacist. ISOPTIN injection contains the active ingredient verapamil hydrochloride. ISOPTIN injection is used to treat ...

In a patient-reported outcome (PRO) survey, Susvimo recipients reported a strong preference for the implant over intraocular injections ... with Roche selling the drug in the US and Novartis ...

After Gov. Bill Lee halted executions in 2022, the department last month announced it created a new lethal injection protocol with a single drug, pentobarbital, to kill the death row inmates ...

After hours: January 13 at 6:22:25 PM EST Loading Chart for DRUG ...

The move comes after news reports from last year that the Hamden company Absolute Standards manufactured the lethal injection drug pentobarbital for use in lethal injections by the federal Bureau ...

Both drugs are complement inhibitors that are administered by intravitreal injection directly into ... were conjunctival haemorrhage (13%), raised intraocular pressure (9%), and blurred vision ...

SOL-1 is being conducted under a Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA), while SOL-R received alignment ... Challenges with current therapies include ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT – WATERTOWN, Mass., (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.